Aquestive Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
About Aquestive Therapeutics
Pharmaceutical Preparations, SIC 2834
Aquestive Therapeutics is a pharmaceutical company that develops and manufactures medicines using proprietary drug delivery technologies, such as its PharmFilm oral soluble film and AdrenaVerse epinephrine prodrug platform. The company designs alternatives to invasive administrations for conditions including severe allergic reactions, central nervous system disorders, and opioid dependence. Its pipeline includes Anaphylm sublingual film for anaphylaxis and AQST-108 topical gel for alopecia areata. Aquestive also collaborates with pharmaceutical partners, serving as an exclusive manufacturer for commercialized licensed products such as Suboxone, Sympazan, and Ondif. Its customers and end users include commercial licensee partners, healthcare providers, and patients requiring alternative drug administration methods.
The company operates manufacturing facilities located in Portage, Indiana, and maintains corporate headquarters along with primary research laboratories in Warren, New Jersey. Aquestive has produced and shipped more than two billion doses of oral films globally, with commercial products distributed in the United States and international markets.
Summary of the business section of Aquestive Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aquestive Therapeutics, Inc.
- Headquarters
- Warren, NJ
- Address
- 184 Liberty Corner Road, Suite 305
- Phone
- (908) 941-1900
- Employees
- 147, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, New Jersey
Stock & identifiers
- Ticker
- AQST
- Exchange
- Nasdaq
- Shares outstanding
- 126M, Aug 7, 2026
- Public float
- $291.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1398733
- CUSIP
- 03843E104
- ISIN
- US03843E1047
- EIN
- 20-8623253
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Barber | President and CEO, Director | 652,317 |
| Sherry Korczynski | Chief Commercial Officer | 235,689 |
| Peter E. Boyd | Chief People Officer | 284,024 |
| Cassie Jung | Chief Operating Officer | 208,833 |
| Thomas A. Zalewski | Chief Legal Officer | 100,000 |
| Melina Cioffi | SVP, Regulatory Affairs | 273,200 |
| Lori J. Braender | Corporate Secretary | 231,042 |
| A. Ernest Toth Jr | Chief Financial Officer | 283,460 |
| Matthew J. Greenhawt | Chief Medical Officer | 77,000 |
| Matthew W. Davis | Chief Development Officer | 100,000 |
| Carl N. Kraus | Chief Medical Officer | 282,475 |
| Stephen Wargacki | Chief Science Officer | 343,552 |
| Julie Krop | Director | 0 |
| Timothy E. Morris | Director | – |
| Gregory B. Brown | Director | 75,085 |
| John Cochran | Director | 99,486 |
| Abigail L. Jenkins | Director | 0 |
| Marco Taglietti | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Daniel Barber | $3.49M | $11.03M | $1.34M | $716 | – |
| FY2024 Daniel Barber | $4.18M | $5.23M | $2.55M | $395 | – |
| FY2024 Keith Kendall | $0 | $0 | $2.55M | $395 | – |
| FY2023 Daniel Barber | $2.50M | $3.28M | $1.15M | $224 | – |
| FY2023 Keith Kendall | $0 | $0 | $1.15M | $224 | – |
| FY2022 Daniel Barber | $1.33M | $704.73K | $872.97K | $23 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 147 colleagues.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 15, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 20, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 27, 2008 | Name change | Name changed from MonoSol Rx, Inc. to Aquestive Therapeutics, Inc. |